Compounded Semaglutide vs. Brand-Name Ozempic/Wegovy: What Clinics Need to Know

If you run a weight management clinic, you have almost certainly had this conversation: a patient asks why they should use compounded semaglutide instead of Ozempic or Wegovy. Or your compliance officer asks whether you should still be offering compounded GLP-1s at all.

The answer is nuanced — and it changed significantly in 2025 and 2026 as the FDA updated its shortage list status for semaglutide and tirzepatide. Here is what every clinic prescriber needs to understand.

Brand-name products (Ozempic, Wegovy, Rybelsus for semaglutide; Mounjaro, Zepbound for tirzepatide) are FDA-approved drugs with specific approved indications, dosing, and labeling. They are manufactured by Novo Nordisk and Eli Lilly respectively.

Compounded semaglutide is prepared by a licensed 503A compounding pharmacy on a patient-specific basis. It is not FDA-approved as a finished drug product — it is compounded under the 503A exemption, which requires a valid patient-specific prescription and a documented medical need.

The FDA's position on compounded GLP-1s shifted materially in 2025–2026. When semaglutide and tirzepatide were on the FDA drug shortage list, 503A and 503B compounders had broader latitude to produce copies of those drugs. Once the FDA removed those drugs from the shortage list, that specific basis for compounding largely disappeared.

What this means for your clinic:

• Compounding a copy of a commercially available, non-shortage drug is generally not permitted under 503A unless there is a documented patient-specific reason the commercial product cannot be used (e.g., allergy to an inactive ingredient, need for a different strength or form not commercially available)
• The "shortage" justification is no longer available for standard semaglutide or tirzepatide in most cases
• Clinics should work with their legal counsel and compounding pharmacy partners to ensure their current prescribing practices have a valid 503A basis

Despite the shortage list changes, there are still legitimate clinical scenarios where compounded semaglutide or tirzepatide may be appropriate:

1. Patient-specific allergies to inactive ingredients in the commercial formulation
2. Dosing requirements not available in commercial products (e.g., very low starting doses for sensitive patients)
3. Alternative delivery forms (sublingual troches for patients who cannot tolerate injections)
4. Combination formulations that are not commercially available

Each of these requires documentation of the specific patient need in the medical record.

Brand-name GLP-1s remain expensive and access-limited. Prior authorization requirements, insurance coverage gaps, and supply constraints continue to affect patient access. These are real clinical and business considerations — but they are not, by themselves, a sufficient basis for 503A compounding under current FDA guidance.

We work only with 503A and 503B compounding pharmacies that maintain rigorous compliance with current FDA guidance. Our team — which includes attorneys with pharmaceutical regulatory backgrounds — monitors FDA 503A/503B guidance in real time.

If you have questions about whether your current prescribing practices have a valid 503A basis, we strongly recommend consulting with a pharmaceutical regulatory attorney. We can connect you with resources through our network.

Ready to get connected with a compliant 503A supply partner? Apply for portal access — NPI verified in 60 seconds.

Related reading: 503A vs 503B: Key Differences · How Onboarding Works · Compliance Standards